SynOx Therapeutics Ltd is a groundbreaking company solely focused on developing emactuzumab, a top-tier monoclonal antibody for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies. With a passionate team of industry veterans who possess extensive experience in bringing biological products through to approval and commercialization, SynOx is dedicated to advancing emactuzumab as a cutting-edge treatment option.

The company's mission is deeply rooted in empowering patients to take control of their treatment journey. By leveraging their industry-leading knowledge and expertise, SynOx aims to address the unmet needs of as many patients as possible and enhance their quality of life. The exceptional safety profile and promising efficacy of emactuzumab in TGCT patients demonstrate its potential to alleviate debilitating pain and disability caused by this rare disease.

Led by a seasoned team of industry professionals and supported by premier life sciences investors, SynOx Therapeutics is committed to revolutionizing the field of macrophage-mediated diseases and improving patient outcomes worldwide.